文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

卡塔尔SARS-CoV-2 Delta变异株与Beta变异株感染者疾病严重程度比较

Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar.
PubMed 文献 · JAMA Intern Med · 2022-01-01
一句话结论倾向评分匹配队列显示,Delta变异株感染较Beta变异株感染住院风险更高(27.3% vs 20.0%,P=0.01),未接种疫苗与重症风险升高相关。

该回顾性队列研究利用卡塔尔全国COVID-19数据库,纳入2021年3月22日至7月7日确诊SARS-CoV-2感染者,Delta变异株感染者与Beta变异株感染者经倾向评分匹配为451对。Delta组住院率27.3%(95%CI 23.2%-31.6%)高于Beta组20.0%(95%CI 16.4%-24.0%),P=0.01;轻中或重危疾病结局27.9% vs 20.2%,P=0.01。Delta感染与任何不良结局的调整OR为2.53(95%CI 1.72-3.72)。感染前超过3个月完成第二剂疫苗接种者,Delta组aOR 0.11(95%CI 0.04-0.26)、Beta组aOR 0.22(95%CI 0.05-0.98);仅单剂接种未见保护。

要点

  • Delta变异株感染较Beta变异株感染住院风险更高:27.3%(95%CI 23.2%-31.6%)vs 20.0%(95%CI 16.4%-24.0%),P=0.01。
  • Delta变异株感染与任何不良结局独立相关:调整OR 2.53(95%CI 1.72-3.72)。
  • 轻中或重危疾病结局:Delta组27.9%(95%CI 23.8%-32.3%)vs Beta组20.2%(95%CI 16.6%-24.2%),P=0.01。
  • 感染前超过3个月完成第二剂疫苗:Delta组aOR 0.11(95%CI 0.04-0.26),Beta组aOR 0.22(95%CI 0.05-0.98)。
  • 仅单剂接种与重症结局降低无显著关联:Delta组aOR 1.12(95%CI 0.41-3.06),Beta组aOR 0.74(95%CI 0.20-2.72)。

适用人群与场景

  • 2021年3月22日至7月7日期间在卡塔尔经逆转录聚合酶链反应检测确诊SARS-CoV-2感染者,Delta变异株感染者与Beta变异株感染者经倾向评分匹配为451对。
  • 数据来自卡塔尔全国COVID-19数据库,包含所有曾接受SARS-CoV-2检测者及所有接种任何SARS-CoV-2疫苗者。

诊断标准与关键阈值

  • 变异株通过阳性样本的变异基因分型确定。

研究设计与关键结果

  • 研究类型:回顾性队列研究;Delta组1427人(252例[55.9%]男性;中位年龄34岁[IQR 17-43岁]),Beta组5353人(233例[51.7%]男性;中位年龄34岁[IQR 17-45岁]),经倾向评分匹配为451对。
  • 主要结局:Delta组住院27.3%(95%CI 23.2%-31.6%)vs Beta组20.0%(95%CI 16.4%-24.0%),P=0.01;轻中或重危疾病结局Delta组27.9%(95%CI 23.8%-32.3%)vs Beta组20.2%(95%CI 16.6%-24.2%),P=0.01。
  • Delta变异株感染与任何不良结局独立相关:调整OR 2.53(95%CI 1.72-3.72)。
  • 感染前超过3个月接种第二剂疫苗 vs 未接种:Delta组任何不良结局aOR 0.11(95%CI 0.04-0.26),Beta组aOR 0.22(95%CI 0.05-0.98)。
  • 感染前不足3个月接种第二剂疫苗者保护作用相似;仅单剂接种与重症结局降低无显著关联:Delta组aOR 1.12(95%CI 0.41-3.06),Beta组aOR 0.74(95%CI 0.20-2.72)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究;原文未报告证据等级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,Delta变异株感染较Beta变异株感染与更严重的疾病相关,未接种疫苗与重危疾病风险升高相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The Delta variant is now the predominant circulating SARS-CoV-2 strain worldwide. Severity of illness in persons infected with the SARS-CoV-2 Delta variant compared with the Beta variant is not known.

OBJECTIVE: To directly compare clinical outcomes in persons infected with the SARS-CoV-2 Delta variant vs those infected with the Beta variant in Qatar.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the national COVID-19 database in Qatar, which includes information on all individuals who were ever tested for SARS-CoV-2 using a reverse transcriptase-polymerase chain reaction test and all individuals who received any SARS-CoV-2 vaccine in Qatar. Among persons with confirmed SARS-CoV-2 infection between March 22 and July 7, 2021, those infected with the Delta variant were identified and were propensity score matched with control individuals infected with the Beta variant. The variants were ascertained by variant genotyping of the positive samples.

EXPOSURES: SARS-CoV-2 infection with the Delta or Beta variant.

MAIN OUTCOMES AND MEASURES: The main outcomes were admission to the hospital, admission to the intensive care unit, use of supplemental oxygen, use of high-flow oxygen, receipt of mechanical ventilation, or death among those infected with the Delta or Beta variant overall and stratified by vaccination status.

RESULTS: Among 1427 persons infected with the Delta variant (252 [55.9%] male; median age, 34 years [IQR, 17-43 years]) and 5353 persons infected with the Beta variant (233 [51.7%] male; median age, 34 years [IQR, 17-45 years]), 451 propensity score-matched pairs were identified. Persons infected with the Delta variant were more likely to be hospitalized (27.3% [95% CI, 23.2%-31.6%] vs 20.0% [95% CI, 16.4-24.0]; P = .01) or to have mild-moderate or severe-critical disease outcomes (27.9% [95% CI, 23.8%-32.3%] vs 20.2% [95% CI, 16.6%-24.2%]; P = .01) compared with persons infected with the Beta variant. Infection with the Delta variant was independently associated with higher odds of experiencing any adverse outcome (adjusted odds ratio [aOR], 2.53; 95% CI, 1.72-3.72). Compared with being unvaccinated, being vaccinated with a second dose more than 3 months before infection was associated with lower odds of any adverse outcome among persons infected with the Delta variant (aOR, 0.11; 95% CI, 0.04-0.26) and among those infected with the Beta variant (aOR, 0.22; 95% CI, 0.05-0.98). Protection was similar among those who received a second vaccine dose less than 3 months before infection, but having received only a single dose was not associated with a lower odds of any severe outcome among those infected with the Delta variant (aOR, 1.12; 95% CI, 0.41-3.06) or those infected with the Beta variant (aOR, 0.74; 95% CI, 0.20-2.72).

CONCLUSIONS AND RELEVANCE: In this cohort study of persons with COVID-19 in Qatar, infection with the SARS-CoV-2 Delta variant was associated with more severe disease than was infection with the Beta variant. Being unvaccinated was associated with greater odds of severe-critical disease.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Butt AA, Dargham SR, Chemaitelly H, et al. Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. JAMA Intern Med. 2022. PMID: 34935861. doi:10.1001/jamainternmed.2021.7949

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。